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Abstract In the present study we confirm the previously
reported high frequency of biochemical markers of mito-
chondrial dysfunction, namely hyperlactacidemia and
increased lactate/pyruvate ratio, in a significant fraction of
210 autistic patients. We further examine the involvement
of the mitochondrial aspartate/glutamate carrier gene
(SLC25A12) in mitochondrial dysfunction associated with
autism. We found no evidence of association of the
SLC25A12 gene with lactate and lactate/pyruvate distri-
butions or with autism in 241 nuclear families with one
affected individual. We conclude that while mitochondrial
dysfunction may be one of the most common medical
conditions associated with autism, variation at the
SLC25A12 gene does not explain the high frequency of
mitochondrial dysfunction markers and is not associated
with autism in this sample of autistic patients.
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Introduction
Autism is a behavioural syndrome characterized by deficits
in social interaction, impaired communication and
restricted and stereotyped behaviours (Folstein & Rosen-
Sheidley, 2001). Although the etiology of autism is unclear,
familiar aggregation of the disease and other disorders of
the spectrum indicate a strong genetic contribution.
A growing number of studies, including detection of
brain metabolism abnormalities and hyperlactacidemia,
imply a disturbance of brain energy metabolism in autistic
patients, which might be a result of mitochondrial oxida-
tive phosphorylation dysfunction in neuronal cells (Lom-
bard, 1998; Chugani, Sundram, Behen, Lee, & Moore,
1999; Graf et al., 2000; Pons et al., 2004). A number of
cases of mitochondrial respiratory chain (MRC) disorders
have been described associated with autism, including a
child with autism and documented MRC complex IV
deficiency by La´szlo, Horvath, Eck, and Fekete (1994), an
autistic boy and his sister with Leigh syndrome with MRC
complex IV defect and a mitochondrial DNA (mtDNA)
G8363A mutation (Graf et al., 2000), two autistic children
with 15q inverted duplication, mitochondrial hyperprolif-
eration and respiratory complex III defect (Filipek et al.,
2003) and five patients with autism and mtDNA mutations
or mtDNA deletion (Pons et al., 2004). In a previous
population-based study of autistic children in Portugal
(Oliveira et al., 2005), we have found hyperlactacidemia, a
biochemical marker of mitochondrial dysfunction, in
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20.3% of 69 tested patients. Mitochondrial functional
studies confirmed the diagnosis of mitochondrial disease in
5 of these patients (7.2%), a surprisingly high frequency in
autism. While the mitochondrial and nuclear genomes
exert a dual genetic control on the biogenesis and main-
tenance of mitochondrial function, in our patients mtDNA
mutations were not detected, suggesting the involvement of
nuclear genes encoding proteins involved in mitochondrial
function (Oliveira et al., 2005).
Recently, a strong association of two polymorphisms
within the SLC25A12 gene, rs2056202 and rs2292813, with
autism has been reported (Ramoz et al., 2004). The
SLC25A12 gene maps to the 2q24-q33 region, where
linkage with autism has previously been found. This gene
spreads over about 110 kb and is expressed primarily as 2.9
and 3.2 kb mRNA species, which encode a 678 amino-acid
protein that is a calcium-dependent aspartate/glutamate
mitochondrial carrier (AGC1). AGC1 plays an important
role in the malate/aspartate shuttle, regulating the cytosolic
redox state that controls conversion of lactate to pyruvate
(Palmieri et al., 2001). We therefore examined whether, in
autistic patients, this gene influences an intermediate bio-
chemical phenotype characteristic of mitochondrial dys-
function, defined by plasma lactate levels and lactate/
pyruvate ratio distribution, and hence might play a role in
the etiology of autism. For this purpose we tested the
association of two SLC25A12 single nucleotide polymor-
phisms (SNP), rs11757 and rs2056202, with plasma lactate
levels, lactate/pyruvate ratio, with autism and with autism
associated with mitochondrial dysfunction, in a population
sample of 241 nuclear families with one affected individ-
ual. While an association of rs2056202 with autism was
reported by Ramoz et al., rs11757, located in the
SLC25A12 gene’s regulatory region, was not tested in that
previous study.
Methods
241 autistic nuclear families were recruited at Hospital
Pedia´trico de Coimbra (HP). Patients were diagnosed as
previously described (Oliveira et al., 2005) and only idio-
pathic subjects and patients with mitochondrial disease
were included in the study. Controls were healthy adult
blood donors.
Plasma lactacte and pyruvate levels were measured
enzymaticaly (Vassault, Bonnefont, Specola, & Saudubray,
1991). Measurement of muscle respiratory chain complex
activities in isolated deltoid muscle mitochondria and
mtDNA study were performed as previously described
(Oliveira et al., 2005). The clinical/laboratorial classifica-
tion of these patients was according to the revision by
Bernier et al. (2002) of current diagnostic criteria in adults
for application to paediatric age. Mental retardation and
hyperlactacidemia were considered minor criteria. Enzy-
matic complex activity (expressed as a ratio to citrate
synthase) less than 20% and between 20–30% of the nor-
mal mean in muscle were major and minor criteria,
respectively. MRC disorder was considered definite if two
major or one major plus two minor criteria were present,
probable if one major plus one minor or at least three
minor criteria were present, and possible if one major or
two minor criteria (one of which must be laboratorial) were
present.
The Ethical Committee at the HP approved the collec-
tion of data and biological specimens from patients for
research purposes, and all participants signed an informed
consent.
Two SNPs at the SLC25A12 gene were tested: rs11757
in the 5¢UTR region and rs2056202 in intron 3–4. PCR
conditions in 12.5 ll were: 25 ng gDNA, 200lM dNTP,
2 mM MgCl2, Taq polymerase, 0.4 lM primers (F: 5¢-
GGAAAGCCACTATGAACATG-3¢;R: 5¢-TATTGATTA
TTGCCCAGTTT-3¢ for rs2056202; F: 5¢-TGATAAAAGG
CATAACGAGA-3¢;R: 5¢-TGAAGGGAAATTGTGAAAG
T-3¢ for rs11757), 30 cycles of 30¢¢/94C, 30¢¢/46C,
30¢¢/72C, followed by 10 min 72C. PCR products for
rs2056202 were digested with HpyCH4IV (New England
Biolabs) and for rs11757 with MaeIII (Roche) and sepa-
rated on 2.5% agarose gel.
Linkage disequilibrium was tested using the family-
based association test (FBAT). Haplotypes were analysed
using TRANSMIT. Genotypic and allele frequencies
between groups were compared using a chi-square test.
Association with the distribution of plasma lactate levels
and pyruvate/lactate ratio was tested with the Kruskal–
Wallis nonparametric test. Linkage disequilibrium between
the two markers was assessed by Lewontin’s D¢, using the
GOLD program.
Results
Plasma lactacte and pyruvate levels were measured in 210
subjects from this sample. Of 210 patients, 36 (17.2%) had
hyperlactacidemia and 53 out of 192 patients (27.6%)
had elevated lactate/pyruvate ratio. No association of either
polymorphism or their haplotypes was found with lactate
level distribution (rs11757: H(2, N = 197) = 1.813,
P = 0.404; rs2056202: H (2, N = 199) = 1.261, P = 0.5323;
haplotypes: H (6, N = 192) = 3.867, P = 0.6947) or with
lactate/pyruvate plasma ratios (rs11757:H (2, N = 183) =
2.725, P = 0.2561; rs2056202: H (2, N = 183) =
0.259, P = 0.8784; haplotypes: H (6, N = 177) = 3.986,
P = 0.6786). The four possible haplotypes were found in our
population, and the two markers are located far apart in the
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chromosome (71,44 kb). However, they were found to be in
strong linkage disequilibrium (D¢ = 0.832).
From the group of 36 patients with hyperlactacidemia,
20 have been fully assessed for mitochondrial disease, and
in seven the diagnosis has been confirmed. Allele and
genotype frequencies for the two markers and their hapl-
otypes were compared between: autistic patients with
mitochondrial disease, autistic patients with no evidence of
mitochondrial dysfunction (no hyperlactacidemia or high
lactate/pyruvate ratios), autistic individuals with hyperlac-
tacidemia or high lactate/pyruvate ratio, and controls. No
significant differences in allele or genotype frequencies
were found between any of these groups (Table 1).
In 241 nuclear families no transmission disequilibrium
was found for either SLC25A12 marker alleles (FBAT:
Z = 0.873, P = 0.3827 for rs2056202; Z = 0.75,
P = 0.4535 for rs11757) or haplotypes of the two
(TRANSMIT: v2 = 2.875, df = 3, P = 0.4113).
Discussion
Our results in this population sample suggest that mito-
chondrial disease may be one of the most common med-
ical conditions associated with autism. Genetic variation at
the SLC25A12 gene, however, did not explain the high
frequency of mitochondrial dysfunction markers in our
patients, such as hyperlactacidemia and high lactate/
pyruvate ratio. Because hyperlactacidemia and increased
lactate/pyruvate ratio may be due to one of several
inherited metabolic defects of gluconeogenesis, pyruvate
oxidation, the Krebs cycle or the respiratory chain, it is
possible that multiple genes influence the observed chan-
ges in lactate and pyruvate levels, and that genetic het-
erogeneity underlies mitochondrial dysfunction associated
with autism. Supporting this hypothesis is the fact that,
even in the limited number of patients with confirmed
mitochondrial disease in our study, we find deficiencies in
more than one respiratory chain complexes (Oliveira
et al., 2005). The findings also do not corroborate the
recently described association of autism with the
SLC25A12 gene (Ramoz et al., 2004). Again, this dis-
crepancy may reflect the expected genetic heterogeneity in
autism indicating that, if SLC25A12 variants indeed play a
role in autism, a different physiologic mechanism may be
involved. It would be interesting to find out if biochemical
markers of mitochondrial dysfunction are present in the
population where association with SLC25A12 has been
found. The results therefore do not necessarily dismiss
SLC25A12 gene as a susceptibility factor, and analysis in
additional populations will be required for a definite
conclusion.
In our population, any deleterious variants of SLC25A12
associated with autism are not frequently represented,
either in the total sample or in the subgroups of autistic
patients with biochemical markers of mitochondrial
dysfunction or confirmed mitochondrial disease. Analysis
of other nuclear genes encoding mitochondrial proteins
will be required to understand the molecular basis of
autism associated with mitochondrial dysfunction.
Table 1 (A) Allele frequencies of rs11757, rs2056202 and
haplotypes in controls and in autistic patients’ subgroups; (B)
Results of the comparison of allelic frequencies between different
subgroups: Subgroup 1: Autistic Patients with mitochondrial disease;
Subgroup 2: Autistic Patients with normal lactate levels; Subgroup 3:
Autistic Patients with hyperlactacidemia; Subgroup 4: Autistic
Patients with high lactate/pyruvate ratio; Subgroup 5: Autistic
Patients with normal lactate/pyruvate ratio
(A)
Population Controls Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 Subgroup 5
Markers/Alleles
rs11757 G N = 60 (67%) N = 11 (92%) N = 243 (72%) N = 48 (73%) N = 70 (70%) N = 185 (69.5%)
C N = 30 (33%) N = 1 (8%) N = 95 (28%) N = 18 (27%) N = 30 (30%) N = 81 (30.5%)
rs2056202 C N = 80 (87%) N = 10 (100%) N = 282 (87%) N = 54 (87%) N = 87 (87%) N = 234 (88%)
T N = 12 (13%) N = 0 (0%) N = 42 (13%) N = 8 (13%) N = 13 (13%) N = 32 (12%)
Haplotypes rs11757/
rs2056202
GC N = 48 (59%) N = 9 (90%) N = 197 (58.6%) N = 36 (62%) N = 54 (57.4%) N = 151 (58%)
CC N = 26 (31%) N = 1 (1%) N = 95 (28.3%) N = 15 (26%) N = 28 (29.8%) N = 79 (30.4%)
GT N = 8 (10%) N = 0 (0%) N = 43 (12.8%) N = 7 (12%) N = 12 (12.8%) N = 29 (11.2%)
CT N = 0 (0 %) N = 0 (0%) N = 1 (0.3%) N = 0 (0%) N = 0 (0%) N = 1 (0.4%)
(B)
Controls
vs
Subgroup 1
Subgroup 1
vs
Subgroup 2
Subgroup 2
vs
Subgroup 3
Subgroup 4
vs
Subgroup 5
Subgroup 5
vs
Subgroup 1
rs11757 v2 = 2.058; P = 0.151 v2 = 1.391; P = 0.238 v2 < 0.001; P = 0.991 v2 = 0.002; P = 0.965 v2 = 1.742; P = 0.187
rs2056202 v2 = 0.489; P = 0.484 v2 = 0.538; P = 0.484 v2 = 0.037; P = 0.847 v2 = 0.005; P = 0.942 v2 = 0.440; P = 0.507
Haplotypes v2 = 3.831; P = 0.147 v2 = 4.083; P = 0.339 v2 = 0.395; P = 1 v2 = 0.529; P = 1 v2 = 4.16; P = 0.328
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